The combination of trametinib and ganitumab is effective in RAS-mutated PAX-fusion negative rhabdomyosarcoma models.
Katie E HebronXiaolin WanJacob S RothDavid J LiewehrNancy E SealoverWilliam J E FryeAngela KimStacey StaufferOlivia L PerkinsWenyue SunKristine A IsanogleChristina M RobinsonAmy JamesParirokh AwasthiPriya ShankarappaXiaoling LuoHaiyan LeiDonna ButcherRoberta SmithElijah F EdmondsonJin-Qiu ChenNoemi KedeiCody J PeerJack F ShernWilliam Douglas FiggLu ChenMatthew D HallSimone DifilippantonioFrederic G BarrRobert L KortumRobert W RobeyAngelina V VasevaJaved KhanMarielle E YohePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
We demonstrate that combined trametinib and ganitumab is effective in a genomically diverse panel of RAS-mutated FN RMS preclinical models.
Keyphrases